Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 5 studies | 21% ± 7% | |
epithelial cell | 5 studies | 22% ± 6% | |
astrocyte | 4 studies | 20% ± 5% | |
hematopoietic precursor cell | 3 studies | 24% ± 2% | |
microglial cell | 3 studies | 19% ± 1% | |
lymphocyte | 3 studies | 17% ± 1% | |
GABAergic neuron | 3 studies | 31% ± 3% | |
glutamatergic neuron | 3 studies | 45% ± 4% | |
dendritic cell | 3 studies | 22% ± 3% | |
macrophage | 3 studies | 20% ± 3% | |
transit amplifying cell | 3 studies | 42% ± 24% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 1822.32 | 1445 / 1445 | 100% | 46.09 | 183 / 183 |
ovary | 100% | 1684.61 | 180 / 180 | 100% | 23.05 | 429 / 430 |
lung | 100% | 1854.72 | 578 / 578 | 100% | 30.47 | 1150 / 1155 |
breast | 100% | 2176.27 | 459 / 459 | 100% | 30.65 | 1113 / 1118 |
intestine | 100% | 1998.63 | 966 / 966 | 99% | 24.34 | 523 / 527 |
bladder | 100% | 1814.86 | 21 / 21 | 99% | 24.43 | 500 / 504 |
uterus | 100% | 1925.78 | 170 / 170 | 99% | 42.41 | 455 / 459 |
stomach | 100% | 1531.71 | 359 / 359 | 98% | 26.27 | 281 / 286 |
brain | 98% | 1292.12 | 2601 / 2642 | 100% | 23.00 | 703 / 705 |
pancreas | 100% | 1224.65 | 327 / 328 | 98% | 16.06 | 174 / 178 |
thymus | 100% | 1871.82 | 653 / 653 | 96% | 14.68 | 580 / 605 |
prostate | 100% | 1722.34 | 245 / 245 | 95% | 13.88 | 475 / 502 |
skin | 100% | 2764.79 | 1809 / 1809 | 94% | 26.96 | 446 / 472 |
kidney | 100% | 1080.13 | 89 / 89 | 92% | 12.55 | 825 / 901 |
liver | 100% | 804.57 | 225 / 226 | 76% | 9.54 | 308 / 406 |
adrenal gland | 100% | 1295.96 | 258 / 258 | 73% | 7.24 | 169 / 230 |
adipose | 100% | 2091.39 | 1204 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 32.12 | 29 / 29 |
spleen | 100% | 2531.55 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 54.83 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 7.16 | 1 / 1 |
blood vessel | 100% | 1575.08 | 1334 / 1335 | 0% | 0 | 0 / 0 |
muscle | 100% | 1109.24 | 801 / 803 | 0% | 0 | 0 / 0 |
heart | 96% | 970.82 | 827 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 94% | 2656.84 | 875 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 57% | 5.68 | 46 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006325 | Biological process | chromatin organization |
GO_0006281 | Biological process | DNA repair |
GO_0010212 | Biological process | response to ionizing radiation |
GO_0006974 | Biological process | DNA damage response |
GO_0097681 | Biological process | double-strand break repair via alternative nonhomologous end joining |
GO_0097680 | Biological process | double-strand break repair via classical nonhomologous end joining |
GO_0000724 | Biological process | double-strand break repair via homologous recombination |
GO_0007095 | Biological process | mitotic G2 DNA damage checkpoint signaling |
GO_0141112 | Biological process | broken chromosome clustering |
GO_0006259 | Biological process | DNA metabolic process |
GO_0051276 | Biological process | chromosome organization |
GO_0006270 | Biological process | DNA replication initiation |
GO_0035825 | Biological process | homologous recombination |
GO_1990166 | Biological process | protein localization to site of double-strand break |
GO_0033314 | Biological process | mitotic DNA replication checkpoint signaling |
GO_0000076 | Biological process | DNA replication checkpoint signaling |
GO_0000077 | Biological process | DNA damage checkpoint signaling |
GO_0005886 | Cellular component | plasma membrane |
GO_0000922 | Cellular component | spindle pole |
GO_0005813 | Cellular component | centrosome |
GO_0005654 | Cellular component | nucleoplasm |
GO_0090734 | Cellular component | site of DNA damage |
GO_0015629 | Cellular component | actin cytoskeleton |
GO_0016604 | Cellular component | nuclear body |
GO_0016605 | Cellular component | PML body |
GO_0005737 | Cellular component | cytoplasm |
GO_0070532 | Cellular component | BRCA1-B complex |
GO_0005694 | Cellular component | chromosome |
GO_0000794 | Cellular component | condensed nuclear chromosome |
GO_0001673 | Cellular component | male germ cell nucleus |
GO_0035861 | Cellular component | site of double-strand break |
GO_0005634 | Cellular component | nucleus |
GO_0003677 | Molecular function | DNA binding |
GO_0140463 | Molecular function | chromatin-protein adaptor activity |
GO_0042802 | Molecular function | identical protein binding |
GO_0043539 | Molecular function | protein serine/threonine kinase activator activity |
GO_0140031 | Molecular function | phosphorylation-dependent protein binding |
GO_0005515 | Molecular function | protein binding |
Gene name | TOPBP1 |
Protein name | DNA topoisomerase II binding protein 1 TOPBP1 protein DNA topoisomerase 2-binding protein 1 (DNA topoisomerase II-beta-binding protein 1) (TopBP1) (DNA topoisomerase II-binding protein 1) Topoisomerase (DNA) II binding protein 1 |
Synonyms | KIAA0259 |
Description | FUNCTION: Scaffold protein that acts as a key protein-protein adapter in DNA replication and DNA repair . Composed of multiple BRCT domains, which specifically recognize and bind phosphorylated proteins, bringing proteins together into functional combinations . Required for DNA replication initiation but not for the formation of pre-replicative complexes or the elongation stages (By similarity). Necessary for the loading of replication factors onto chromatin, including GMNC, CDC45, DNA polymerases and components of the GINS complex (By similarity). Plays a central role in DNA repair by bridging proteins and promoting recruitment of proteins to DNA damage sites . Involved in double-strand break (DSB) repair via homologous recombination in S-phase by promoting the exchange between the DNA replication factor A (RPA) complex and RAD51 . Mechanistically, TOPBP1 is recruited to DNA damage sites in S-phase via interaction with phosphorylated HTATSF1, and promotes the loading of RAD51, thereby facilitating RAD51 nucleofilaments formation and RPA displacement, followed by homologous recombination . Involved in microhomology-mediated end-joining (MMEJ) DNA repair by promoting recruitment of polymerase theta (POLQ) to DNA damage sites during mitosis . MMEJ is an alternative non-homologous end-joining (NHEJ) machinery that takes place during mitosis to repair DSBs in DNA that originate in S-phase . Recognizes and binds POLQ phosphorylated by PLK1, enabling its recruitment to DSBs for subsequent repair . Involved in G1 DNA damage checkpoint by acting as a molecular adapter that couples TP53BP1 and the 9-1-1 complex . In response to DNA damage, triggers the recruitment of checkpoint signaling proteins on chromatin, which activate the CHEK1 signaling pathway and block S-phase progression . Acts as an activator of the kinase activity of ATR . Also required for chromosomal stability when DSBs occur during mitosis by forming filamentous assemblies that bridge MDC1 and tether broken chromosomes during mitosis . Together with CIP2A, plays an essential role in the response to genome instability generated by the presence of acentric chromosome fragments derived from shattered chromosomes within micronuclei . Micronuclei, which are frequently found in cancer cells, consist of chromatin surrounded by their own nuclear membrane: following breakdown of the micronuclear envelope, a process associated with chromothripsis, the CIP2A-TOPBP1 complex tethers chromosome fragments during mitosis to ensure clustered segregation of the fragments to a single daughter cell nucleus, facilitating re-ligation with limited chromosome scattering and loss . Recruits the SWI/SNF chromatin remodeling complex to E2F1-responsive promoters, thereby down-regulating E2F1 activity and inhibiting E2F1-dependent apoptosis during G1/S transition and after DNA damage . . |
Accessions | A0A2R8YD63 ENST00000642236.1 ENST00000572787.1 A0AV47 Q05BV8 I3L1F2 ENST00000260810.10 Q92547 A7E2X7 |